Matthew Rich
Gerontology · Tyler, TXNPI 1639692965
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 355 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 26.2% of the total. Reporting peaked in 2021 at $1,873 and has fallen 52.6% since, to $887 in 2025. Among gerontology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$881
- Otsuka America Pharmaceutical, Inc.$667
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$558
- Lundbeck LLC$430
- Vanda Pharmaceuticals Inc.$271
- plus $1K from 15 others
What the payments were for
- Food & beverage$5,42999%
- Education$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 120 | $1,443 |
| Alkermes, Inc. | 40 | $881 |
| Otsuka America Pharmaceutical, Inc. | 45 | $667 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $558 |
| Lundbeck LLC | 23 | $430 |
| Vanda Pharmaceuticals Inc. | 17 | $271 |
| Indivior Inc. | 15 | $227 |
| Sunovion Pharmaceuticals Inc. | 20 | $208 |
| Neurocrine Biosciences, Inc. | 10 | $190 |
| Johnson & Johnson | 6 | $131 |
| Teva Pharmaceuticals USA, Inc. | 6 | $130 |
| E.r. Squibb & Sons, L.L.C. | 4 | $94 |
| Axsome Therapeutics, Inc. | 3 | $55 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $52 |
| Jazz Pharmaceuticals Inc. | 3 | $42 |
| Eisai Inc. | 2 | $41 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Biogen | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $14 |
| Amgen | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$468
- LYBALVI$459
- ARISTADA INITIO$117
How this compares
$5,503 in reported general payments places this provider in the 90th percentile of 653 gerontology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 144 | $210,750 |
| VraylarCariprazine Hcl | 144 | $200,733 |
| AustedoDeutetrabenazine | 21 | $157,563 |
| Invega TrinzaPaliperidone Palmitate | 16 | $121,060 |
| UzedyRisperidone | 21 | $77,435 |
| Invega SustennaPaliperidone Palmitate | 19 | $62,135 |
| LybalviOlanzapine/Samidorphan Malate | 27 | $42,498 |
| CaplytaLumateperone Tosylate | 20 | $33,973 |
| DayvigoLemborexant | 50 | $16,404 |
| SunosiSolriamfetol Hcl | 15 | $13,172 |
| FetzimaLevomilnacipran Hcl | 26 | $12,459 |
| TrintellixVortioxetine Hydrobromide | 16 | $7,967 |
| Atomoxetine Hcl | 30 | $5,461 |
| Prazosin Hcl | 204 | $4,484 |
| Lurasidone Hcl | 32 | $3,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $130 | $234,99842 claims |
| AbbVieVraylar, Fetzima | $1,443 | $213,192170 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $667 | $210,750144 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $131 | $183,19535 claims |
| Alkermes, Inc.Lybalvi | $881 | $42,49827 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $558 | $33,97320 claims |
| Eisai Inc.Dayvigo | $41 | $16,40450 claims |
| Axsome Therapeutics, Inc.Sunosi | $55 | $13,17215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 gerontology providers in Texas.
Other gerontology in Tyler
- Kimberly WelchCoppell$113K
- Tiffany KesslerDallas$84K
- Jennifer WestFort Worth$67K
- Bailey EstesAbilene$34K
- Scott ZelaHouston$28K
- Marissa Marti-SmithDallas$27K
- Andrew BargerAustin$22K
- Meagan ChavarriaHouston$21K
- Samantha BoggsGalveston$15K
- Amber ArmstrongAustin$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.